Simulations Plus Establishes Distribution Channel in India with Electrolab
20 April 2017 - 10:30PM
Business Wire
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of
modeling and simulation software and consulting services for the
pharmaceutical, biotechnology, and chemicals industries, today
announced that it has signed a distributor agreement in India with
Electrolab India Pvt. Ltd.
John DiBella, vice president for marketing and sales of
Simulations Plus, said: “The Indian pharmaceutical market has
enjoyed robust growth this past decade, especially in the areas of
generic product development and drug delivery, and this is expected
to continue going forward. To capitalize on this opportunity, we
are excited to be partnering with Electrolab, an established
company with strong relationships throughout India, whose sound
reputation for providing high-quality products and customer support
has allowed them to capture more than 70% of the market share in
the pharmaceutical equipment space. We expect Electrolab’s
expertise in dissolution and absorption testing to complement our
offerings well. The extensive sales and technical support network
should allow us to further penetrate the Indian market, helping us
achieve our strategic goals.”
Aditya Marfatia, Director at Electrolab, added: “The use of drug
discovery and simulation software has increased in North America
and Europe over the past decade, and we strongly believe increased
adoption within the Indian pharmaceutical industry will help bring
new drugs and generic products to market in a faster and more
cost-effective way. We are excited to be partnering with
Simulations Plus, whose industry-leading software programs have
been successfully referenced in numerous regulatory submissions. We
look forward to increasing awareness of this technology with
Simulations Plus and supporting users throughout India.”
About Simulations Plus, Inc.
Simulations Plus, Inc. is a premier developer of drug discovery
and development software as well as a leading provider of both
preclinical and clinical pharmacometric consulting services for
regulatory submissions. The company is a global leader focused on
improving the ways scientists use knowledge and data to predict the
properties and outcomes of pharmaceutical and biotechnology agents.
Our software is licensed to and used in the conduct of drug
research by major pharmaceutical and biotechnology companies and
regulatory agencies worldwide. Our innovations in integrating new
and existing science in medicinal chemistry, computational
chemistry, pharmaceutical science, biology, and physiology into our
software have made us the leading software provider for
physiologically based pharmacokinetic modeling and simulation. For
more information, visit our website at
www.simulations-plus.com.
About Electrolab (India) Pvt. Ltd.
Established in 1984, Electrolab manufactures pharmaceutical
testing equipment and peristaltic pumps which are used in several
industries. Electrolab is the leading provider of dissolution and
allied equipment in India with a presence in most of the
pharmaceutical companies. Its extensive technical sales and support
network around India allows for prompt local support and has helped
Electrolab evolve into a highly successful sales, marketing,
service and support organization. For more information, visit our
website at www.electrolabgroup.com.
Safe Harbor Statement Under the Private Securities Litigation
Reform Act of 1995 – With the exception of historical
information, the matters discussed in this press release are
forward-looking statements that involve a number of risks and
uncertainties. Words like “believe,” “expect” and “anticipate” mean
that these are our best estimates as of this writing, but that
there can be no assurances that expected or anticipated results or
events will actually take place, so our actual future results could
differ significantly from those statements. Factors that could
cause or contribute to such differences include, but are not
limited to: our ability to maintain our competitive advantages,
acceptance of new software and improved versions of our existing
software by our customers, the general economics of the
pharmaceutical industry, our ability to finance growth, our ability
to continue to attract and retain highly qualified technical staff,
our ability to identify and close acquisitions on terms favorable
to the Company, and a sustainable market. Further information on
our risk factors is contained in our quarterly and annual reports
as filed with the U.S. Securities and Exchange Commission.
Follow us on Twitter | LinkedIn
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170420005254/en/
Simulations Plus Investor
RelationsMs. Renee Bouche,
661-723-7723renee@simulations-plus.comorHayden IRMr. Cameron Donahue,
651-653-1854cameron@haydenir.com
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Apr 2024 to May 2024
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From May 2023 to May 2024